First- and second-line treatment strategies for hormone-receptor (HR)-positive HER2-negative metastatic breast cancer: A real-world study
Author:
Publisher
Elsevier BV
Subject
General Medicine,Surgery
Reference42 articles.
1. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer;Hortobagyi;Ann Oncol,2018
2. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3;Slamon;J Clin Oncol,2018
3. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer;Johnston,2019
4. The effect of Abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy - monarch 2: a randomized clinical trial;Sledge;JAMA Oncology,2019
5. PALOMA-2: primary results from a phase III trial of palbociclib (P) with letrozole (L) compared with letrozole alone in postmenopausal women with ER+/HER2– advanced breast cancer (ABC);Finn;J Clin Oncol,2016
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Real-world treatment patterns and outcomes in patients with HR+/HER2− metastatic breast cancer treated with chemotherapy in the United States;ESMO Open;2024-09
2. A novel framework to assess haematology and oncology registration trials: The THEOREMM project;European Journal of Clinical Investigation;2024-06-27
3. Identifying drivers of first-line HR+/HER2− metastatic breast cancer treatment choices;Future Oncology;2024-06-04
4. Oncotype DX in Breast Cancer Management: Insights and Outcomes From the United Arab Emirates;Cureus;2024-03-20
5. Real-world comparative effectiveness of palbociclib plus aromatase inhibitor in HR+/HER2- metastatic breast cancer;Future Oncology;2024-01-17
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3